TrialJournal of clinical microbiology2005

Benefit of hepatitis C virus core antigen assay in prediction of therapeutic response to interferon and ribavirin combination therapy.

Masahiko Takahashi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.